Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

TAKE CHARGE WITH YORVIPATH



IF YOU'RE LIVING WITH
HYPOPARA, REDEFINE POSSIBLE

Hypopara = hypoparathyroidism.

Not an actual patient.

IMPORTANT SAFETY INFORMATION AND USE

What is YORVIPATH® used for?

YORVIPATH is a prescription medicine used to treat adults with low parathyroid hormone (PTH) (hypoparathyroidism).

- It is not known if YORVIPATH is safe and effective in people who have been recently diagnosed with hypoparathyroidism after surgery, or if it is started in people with low levels of calcium in the blood.
- It is not known if YORVIPATH is safe and effective in children.
- YORVIPATH should not be used in children and young adults whose bones are still growing.

Who should not take YORVIPATH?

Do not use YORVIPATH if you have had a severe allergic reaction to palopegteriparatide or any of the other ingredients in YORVIPATH.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Understanding hypopara and PTH

Hypoparathyroidism (hypopara) is a condition that's characterized by low or missing parathyroid hormone (PTH).

PTH helps your body regulate calcium by sending signals to key organs. When more calcium is needed, PTH enables you to:

Stimulate bones to release stored calcium

Move calcium from the kidneys to the bloodstream

Increase calcium absorption from food in the intestines



"Living with hypopara means I'm always thinking about how my calcium levels will impact my day."

– Lynette, **actual patient**

Conventional therapy alone does not address low or missing PTH

Calcium fluctuations can cause a wide range of symptoms.

✓ Check the symptoms that you experience most frequently

Symptoms of high blood calcium

- NAUSEA
- VOMITING
- DIZZINESS
- CONFUSION
- FEELING THIRSTY
- MUSCLE WEAKNESS
- IRREGULAR HEARTBEAT



Symptoms of low blood calcium

- TINGLING IN YOUR FINGERTIPS, TOES, LIPS, OR TONGUE
- MUSCLE SPASMS OR CRAMPS
- ABNORMAL HEART RHYTHMS
- SEIZURES
- ORAL NUMBNESS
- DEPRESSION
- PROBLEMS WITH THINKING OR REMEMBERING

Still experiencing symptoms?

If you're still experiencing symptoms or your lab results don't match the way you feel, it may be time to talk to your doctor about another treatment option.

See more important questions on page 13.

THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR HYPOPARATHYROIDISM IN ADULTS

YORVIPATH was designed to help provide your body with the PTH it needs



WITH PTH DELIVERED OVER 24 HOURS, YORVIPATH CAN HELP:

- Maintain normal blood calcium levels
- Maintain normal movement of calcium through your bones, blood, and vital organs
- Activate vitamin D to help with calcium absorption



IMPORTANT SAFETY INFORMATION AND USE

What is the most important information I should know about YORVIPATH?

YORVIPATH may cause serious side effects, including:

- **Allergic (hypersensitivity) reactions, including anaphylaxis.** Stop taking YORVIPATH and get medical help right away if you have any of the following symptoms of an allergic reaction: swelling of your face, lips, mouth or tongue, breathing problems, fainting, dizziness, feeling lightheaded (low blood pressure), fast heartbeat, itching, rash or hives.
- **High levels of calcium in the blood (hypercalcemia).** YORVIPATH can cause some people to have higher blood calcium levels than normal. Your healthcare provider should check your blood calcium before you start and during your treatment with YORVIPATH. Tell your healthcare provider right away if you have nausea, vomiting, dizziness, feeling thirsty, confusion, muscle weakness, or irregular heartbeat. Hypercalcemia is more likely to occur within the first 3 months of starting YORVIPATH, but it may occur at any time.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL



“I started taking YORVIPATH because it helps give my body the PTH it needs throughout the day, so I can focus on what matters most to me.”

– Chris, **actual patient,** with Heidi, Chris’ care partner

IMPORTANT SAFETY INFORMATION AND USE

What is the most important information I should know about YORVIPATH? (cont’d)

YORVIPATH may cause serious side effects, including:

- **Low levels of calcium in the blood (hypocalcemia).** People who stop using, miss, or change a dose of YORVIPATH may have an increased risk of low blood calcium levels, but hypocalcemia may occur at any time. Tell your healthcare provider right away if you have tingling in your fingertips, toes, lips or tongue, muscle spasms or cramps, oral numbness, depression, have problems thinking or remembering, abnormal heart rhythms, or seizures.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

YORVIPATH delivers results for people living with hypopara

NEARLY 70%

(68.9% vs 4.8% with placebo) achieved treatment goals while on YORVIPATH at Week 26*†

In a 26-week clinical study of YORVIPATH, all participants were on conventional therapy, then assigned to take either YORVIPATH (61 people) or placebo (21 people).‡

To be considered responsive to treatment with YORVIPATH, people had to meet ALL of these treatment criteria at Week 26:

- Normal blood calcium levels
- Independence from conventional therapy§ since Week 22
- No increase in YORVIPATH doses since Week 22
- No missing conventional therapy data since Week 22
- The YORVIPATH dose was less than or equal to 30 micrograms per day during the entire study

*The placebo injection was meant to act like the YORVIPATH injection, but without any active substances.

†The goal of treatment with YORVIPATH is to maintain normal blood calcium levels without the need for active vitamin D or calcium (more than 600 mg per day). Calcium supplementation needed to meet daily dietary requirements may be continued.

‡Doses for YORVIPATH, placebo, and conventional therapy were adjusted by a doctor based on blood calcium levels.

§Independence from conventional therapy was defined as no active vitamin D or therapeutic calcium (elemental calcium more than 600 mg per day) with no as-needed doses since Week 22, and no missing active vitamin D or calcium data after Week 22 of the study.

IMPORTANT SAFETY INFORMATION AND USE

What is the most important information I should know about YORVIPATH? (cont'd)

YORVIPATH may cause serious side effects, including:

- **Possible bone cancer (osteosarcoma).** Tell your healthcare provider right away if you have pain in any areas of your body that does not go away or any new or unusual lumps or swelling under your skin that is tender to touch. These are some of the signs and symptoms of osteosarcoma and your healthcare provider may need to do further tests.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

Results from individual goals in the study[‖]:

80% had normal calcium levels vs 48% with placebo

87% became independent from daily calcium vs 5% with placebo

93% had no dose increase beyond Week 22 vs 57% with placebo

95% became independent from daily active vitamin D vs 24% with placebo

91.8% of people taking YORVIPATH did not take more than 30 mcg daily at any point during the 26-week study.

In a clinical study, people on YORVIPATH were able to reduce the average number of active vitamin D and calcium pills taken daily



All people in the study were part of this analysis, including those who received YORVIPATH doses of more than 30 micrograms daily at any point during the study.

[‖]At the end of the study, people who responded to treatment with YORVIPATH had reduced their average daily dose of calcium to 600 mg or less (with none taken as needed) and had eliminated their need for daily active vitamin D. An additional measure of effectiveness was that responders to YORVIPATH did not have any missing active vitamin D or calcium data after Week 22 of the study.

IMPORTANT SAFETY INFORMATION AND USE

Who should not take YORVIPATH?

Do not use YORVIPATH if you have had a severe allergic reaction to palopegteriparatide or any of the other ingredients in YORVIPATH.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

IN A 26-WEEK CLINICAL STUDY OF PEOPLE LIVING WITH HYPOPARA,

YORVIPATH was generally safe and well-tolerated

MOST COMMON SIDE EFFECT

Injection site reactions

OTHER SIDE EFFECTS INCLUDED

A drop in blood pressure or lightheadedness when standing up, headache, diarrhea, back pain, high blood calcium levels, and sore throat

No one stopped taking YORVIPATH due to side effects during the 26-week clinical study

While on YORVIPATH, you may experience signs or symptoms of low or high blood calcium levels. If so, you should discuss these with your doctor.

IMPORTANT SAFETY INFORMATION AND USE

What should I tell my healthcare provider before taking YORVIPATH?

Before using YORVIPATH, tell your healthcare provider about all of your medical conditions, including if you:

- are at higher risk of a type of bone cancer called osteosarcoma. This is especially important:
  - if you have a bone disease that increases your risk of developing osteosarcoma (including if you have Paget's disease).
  - if a blood test shows that you have unexplained increases in bone alkaline phosphatase.
  - if you have cancer of the bones or other cancer that has spread to your bones.
  - if you are having or have had radiation therapy to the skeleton.
  - if you are affected with a condition that runs in your family that can increase your chance of getting cancer in your bones.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

ONCE-DAILY injection in a convenient, ready-to-use pen



Not actual size.

You will work closely with your doctor to find the dose that is right for you, starting with the 18-microgram dose. Your doctor will also adjust your doses of calcium and active vitamin D.

Learn more about taking YORVIPATH at YORVIPATH.com

IMPORTANT SAFETY INFORMATION AND USE

What should I tell my healthcare provider before taking YORVIPATH? (cont'd)

Before using YORVIPATH, tell your healthcare provider about all of your medical conditions, including if you:

- take medicines that contain digoxin, are used to treat osteoporosis, or can affect calcium levels in your blood.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

Get personalized support at each step in your treatment journey

A·S·A·P
ASCENDIS SIGNATURE ACCESS PROGRAM®

Once enrolled in A·S·A·P, you will have access to a team of caring professionals providing you support throughout your treatment journey, including:

- Understanding insurance coverage
- Starting treatment with a YORVIPATH Starter Kit
- Refills and ongoing support to stay on track with YORVIPATH
- Connecting you to a Patient Access Liaison (PAL)

Your PAL can help you understand your insurance and benefits, learn more about your condition, and see how YORVIPATH may fit into your treatment plan.

IMPORTANT SAFETY INFORMATION AND USE

What should I tell my healthcare provider before taking YORVIPATH? (cont'd)

Before using YORVIPATH, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant or plan to become pregnant. It is not known if YORVIPATH will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with YORVIPATH.
- are breastfeeding or plan to breastfeed. It is not known if YORVIPATH passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with YORVIPATH.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YORVIPATH and other medicines may affect each other causing side effects.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

Pay as little as $5 per month for your YORVIPATH prescription*

If you have commercial health insurance and are eligible, you may pay as little as $5 per month for YORVIPATH*

If you do not have insurance or are underinsured, **you may qualify for treatment at $0** through the Ascendis Patient Assistance Program (PAP).†



Visit YORVIPATH.com to learn more about personalized support with A·S·A·P.

To talk to a member of our support team or get connected to a PAL, call 1-844-442-7236 (8 AM to 8 PM ET, Monday through Friday).

*Eligibility required. Federal and state healthcare beneficiaries are ineligible (participants in programs such as Medicaid, Medicare, Medigap, VA, DOD, or TRICARE). Offer not valid for cash-paying patients. Terms and conditions apply.

†Full terms, conditions, and eligibility criteria apply.

IMPORTANT SAFETY INFORMATION AND USE

What are the possible side effects of YORVIPATH?

YORVIPATH may cause serious side effects:

- **Decrease in blood pressure when you change positions (orthostatic hypotension).** Some people may feel dizzy, get a fast heartbeat, or feel light-headed right after injecting YORVIPATH. For the first few doses, give your injection of YORVIPATH in a place where you can sit or lie down right away if you get these symptoms. If your symptoms get worse or do not go away, contact your healthcare provider before you continue using YORVIPATH.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

Real people living with hypopara are taking charge



> **“So far for me, the biggest difference is that I feel like I’m able to more predictably manage my hypoparathyroidism.”**
>
> – Joanna, **actual patient**

Hear more stories from people like you at YORVIPATH.com

IMPORTANT SAFETY INFORMATION AND USE

What are the possible side effects of YORVIPATH? (cont’d)

YORVIPATH may cause serious side effects:

- **Digoxin toxicity if you are using digoxin and YORVIPATH at the same time.** Tell your healthcare provider if you experience irregular heart rhythm, heart palpitations, confusion, loss of appetite, nausea, vomiting, diarrhea, or vision problems.

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

Take a moment to reflect on how you feel and your goals for managing hypopara

How would you rate how you currently feel on a daily basis:



MENTALLY

PHYSICALLY

EMOTIONALLY

How much does taking calcium and active vitamin D impact your daily life?

NEVER **RARELY** **SOMETIMES** **FREQUENTLY**

On average, how often do the symptoms of high and low calcium impact your daily life?

NEVER **RARELY** **SOMETIMES** **FREQUENTLY**

How well do you think you're able to manage your hypopara?



When it comes to managing your hypopara, do you have any goals that you're working toward?

Additional notes or topics you'd like to share with your doctor:

See if YORVIPATH could be right for you

- 24-hour delivery of PTH
- Maintains normal blood calcium levels for 24 hours
- Personalized support throughout treatment with enrollment in A·S·A·P

Ready to *redefine possible* with **hypopara**?

Ask your doctor about starting YORVIPATH

Learn more at YORVIPATH.com

Actual patients were compensated by Ascendis Pharma.

IMPORTANT SAFETY INFORMATION AND USE

What are the possible side effects of YORVIPATH? (cont'd)

The most common side effects of YORVIPATH include injection site reactions, vasodilatory signs or symptoms such as a drop in blood pressure or lightheadedness when standing up, headache, diarrhea, back pain, high calcium levels, and sore throat.

These are not all of the possible side effects of YORVIPATH. Call your doctor for medical advice about side effects. **You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.**

Please see Important Safety Information throughout. Please click to read or print the Prescribing Information and Medication Guide for YORVIPATH.

Yorvipath®
palopegteriparatide
Injection 300 mcg/mL

ascendis pharma

© August 2026 Ascendis Pharma Endocrinology, Inc. All rights reserved. YORVIPATH®, Ascendis Signature Access Program®, Ascendis®, the Ascendis Pharma logo and the company logo are trademarks owned by the Ascendis Pharma Group. US-COMMPTH-2600153 08/26